Adam's Take - Page 3 of 6

Adam's Take

And now, your nominees for worst biopharma CEO of 2018. Let the voting begin!

By Adam Feuerstein

Adam's Take

Introducing the nominees for best biopharma CEO of 2018. Vote for your favorite!

By Adam Feuerstein

Adam's Take

Why Gilead’s new CEO is a solid choice to help the biotech grow again

By Adam Feuerstein

Adam's Take

Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy

By Adam Feuerstein

Adam's Take

Ziopharm shares are moving higher on a turnaround strategy, but is it for real? A closer look

By Adam Feuerstein

Adam's Take

If biotech stock values are down, why isn’t M&A picking up?

By Adam Feuerstein

Adam's Take

Biotech is looking woozy: ferocious selling and a sense of foreboding

By Adam Feuerstein

Adam's Take

Amarin, Vascepa, and mineral oil. There is more to consider with this fish-oil drug story

By Adam Feuerstein

Adam's Take

Skin cancer immunotherapy could have potential but don’t hang hopes on new data

By Adam Feuerstein

Adam's Take

Acadia Pharma conjures black magic to spin a failed depression drug trial

By Adam Feuerstein

Adam's Take

Beyond the headline: Mirati undersells concerning data on its lung cancer immunotherapy

By Adam Feuerstein

Adam's Take

Novartis buys Endocyte for $2.1 billion, causing an outspoken critic to admit he was badly wrong

By Adam Feuerstein

Adam's Take

A biotech company misled investors about its dealings with FDA. It’s time for a reckoning

By Adam Feuerstein

Adam's Take

A tiny fish-oil drug rival trash talks Amarin, but there’s still much to prove

By Adam Feuerstein

Adam's Take

Omeros claims a failed drug study was ‘positive.’ Investors were not fooled

By Adam Feuerstein

Adam's Take

Ahead of Geron blowup, warning signs were visible for those willing to see them

By Adam Feuerstein

Adam's Take

TG Therapeutics’ credibility vanishes with blood cancer drug trial setback

By Adam Feuerstein

Adam's Take

Amarin has investors buzzing about fish oil. Here’s where this biotech feel-good story goes next

By Adam Feuerstein

Adam's Take

Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

By Adam Feuerstein

Adam's Take

Global Blood’s FDA filing plan for a sickle cell drug is riskier than you think

By Adam Feuerstein

Adam's Take

Amgen emerges as new multiple myeloma drug player, threatening Bluebird, Celgene

By Adam Feuerstein

Adam's Take

Answers to biotech’s burning questions for 2018: winners, floppers, and procrastinators

By Adam Feuerstein

Adam's Take

Can plastic tubes stop livers from failing? Unlikely, but a biotech keeps trying

By Adam Feuerstein

Adam's Take

A gene therapy for overactive bladder? A waste of time and money that trivializes a lifesaving technology

By Adam Feuerstein

Business

Investors are pouring more money into biotech funds, and stocks are responding

By Adam Feuerstein

Amarin’s CEO drops enough JPM19 hints to know Vascepa sales driving higher

It’s day one at JPM19. Here’s what we heard and learned

On the cusp of the ‘JPM,’ here’s a cheat sheet for what to watch in biotech in 2019

Leiden victorious in best biopharma CEO tally; Alles tops worst list

And now, your nominees for worst biopharma CEO of 2018. Let the voting begin!

Introducing the nominees for best biopharma CEO of 2018. Vote for your favorite!

Why Gilead’s new CEO is a solid choice to help the biotech grow again

Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy

Ziopharm shares are moving higher on a turnaround strategy, but is it for real? A closer look

If biotech stock values are down, why isn’t M&A picking up?

Biotech is looking woozy: ferocious selling and a sense of foreboding

Amarin, Vascepa, and mineral oil. There is more to consider with this fish-oil drug story

Skin cancer immunotherapy could have potential but don’t hang hopes on new data

Acadia Pharma conjures black magic to spin a failed depression drug trial

Beyond the headline: Mirati undersells concerning data on its lung cancer immunotherapy

Novartis buys Endocyte for $2.1 billion, causing an outspoken critic to admit he was badly wrong

A biotech company misled investors about its dealings with FDA. It’s time for a reckoning

A tiny fish-oil drug rival trash talks Amarin, but there’s still much to prove

Omeros claims a failed drug study was ‘positive.’ Investors were not fooled

Ahead of Geron blowup, warning signs were visible for those willing to see them

TG Therapeutics’ credibility vanishes with blood cancer drug trial setback

Amarin has investors buzzing about fish oil. Here’s where this biotech feel-good story goes next

Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

Global Blood’s FDA filing plan for a sickle cell drug is riskier than you think

Amgen emerges as new multiple myeloma drug player, threatening Bluebird, Celgene

Answers to biotech’s burning questions for 2018: winners, floppers, and procrastinators

Can plastic tubes stop livers from failing? Unlikely, but a biotech keeps trying

A gene therapy for overactive bladder? A waste of time and money that trivializes a lifesaving technology

Investors are pouring more money into biotech funds, and stocks are responding

Adam’s Take